SOCRA CCRP Dumps in PDF and Online - Page: 1

QUESTION: 1

Which of the following is an example of an additional protection required when conducting research on children?

There must be an impartial advocate present during the consent process
The investigator must obtain age-appropriate assent as determined by the IRB/IEC
Parents must be present during all procedures
The study must be approved by a central pediatric IRB

Answer(s): B

Explanation:

Children are a vulnerable population. U.S. regulations require IRB/IEC judgment about when and how assent is obtained, in addition to parental permission. Exact extracts:

45 CFR 46.408(a): "The IRB shall determine ... whether and to what extent children are capable of providing assent."

ICH E6(R2) 4.8.12: "Where a subject is unable to give consent personally, assent should be obtained when appropriate, in accordance with applicable regulatory requirement(s)."

Thus, the additional protection is IRB-determined, age-appropriate assent (B). Options A, C, and D are not universal requirements for all pediatric research.

Reference:

ICH E6(R2) Good Clinical Practice, §4.8.12 (Informed consent/assent).

45 CFR 46 Subpart D--Additional Protections for Children, §46.408(a).

Reveal Solution Next Question

QUESTION: 2

A subject currently on a clinical trial was hospitalized for 2 days due to a SAE. The subject reported the hospitalization to the investigator at the next study visit. According to the ICH GCP Guideline, when should the investigator report the SAE to the sponsor?

Immediately
Within 7 working days
Within 10 working days
Within 15 working days

Answer(s): A

Explanation:

ICH requires immediate reporting of all SAEs to the sponsor (except those protocol-identified as not requiring immediate reporting). Exact extract:

ICH E6(R2) 4.11.1: "The investigator should report all serious adverse events immediately to the sponsor except for those SAEs that the protocol... identifies as not needing immediate reporting."

Therefore, "Immediately" (A) is correct. The other timeframes are not aligned with ICH GCP for initial SAE notification from investigator to sponsor.

Reference:

ICH E6(R2) Good Clinical Practice, §4.11.1 (Safety reporting by investigators).

Reveal Solution Next Question

QUESTION: 3

In accordance with the ICH GCP Guideline, when a sponsor transfers trial-related duties and functions to a contract research organization (CRO), who is ultimately responsible for the quality and integrity of the trial data?

The investigator
The IRB/IEC
The CRO
The sponsor

Answer(s): D

Explanation:

Outsourcing does not shift ultimate responsibility away from the sponsor. Exact extract:

ICH E6(R2) 5.2.1: "A sponsor may transfer any or all of the sponsor's trial-related duties... to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor."

Hence, D is correct.

Reference:

ICH E6(R2) Good Clinical Practice, §5.2.1 (Sponsor/CRO).

Reveal Solution Next Question

QUESTION: 4

During an internal compliance review, the site study team identified that a protocol-required blood sample collection was not obtained for a majority of the subjects enrolled. In accordance with the ICH GCP Guideline, the clinical investigator should:

Suspend all trial-related activities until the events of the deviation have been mitigated
Document and explain the deviation from the protocol
Assign another investigator to perform sample collections until an internal investigation is completed
Immediately report the observation to the regulatory authority

Answer(s): B

Explanation:

ICH directs investigators to document and explain any deviation, with prompt reporting to IRB/IEC only when deviations are implemented to eliminate immediate hazards or as required. Exact extracts:

ICH E6(R2) 4.5.3: "The investigator should document and explain any deviation from the approved protocol."

ICH E6(R2) 3.3.7 & 4.5.2 (paraphrased): deviations to eliminate immediate hazards must be reported as soon as possible.

Here, absent immediate hazard, the required action is documentation and explanation (B).

Reference:

ICH E6(R2) Good Clinical Practice, §4.5.3 (Compliance with protocol; deviations).

ICH E6(R2) §3.3.7; §4.5.2 (Reporting deviations implemented to eliminate immediate hazards).

Reveal Solution Next Question

QUESTION: 5

A coordinator for an ongoing industry-sponsored, multi-site Phase II clinical trial is taking an unexpected, long-term medical absence. The trial site retains coordinator services from an external source to support clinical trial activities. According to the ICH GCP Guideline, which of the following is responsible for implementing procedures to ensure the integrity of the clinical trial-related duties?

The sponsor
The investigator/institution
The IRB/IEC
The external source

Answer(s): B

Explanation:

The investigator/institution bears responsibility for site conduct, oversight of delegated tasks, and ensuring qualified, trained staff--regardless of employment source. Exact extracts:

ICH E6(R2) 4.1.1: "The investigator should be qualified... and have adequate resources to properly conduct the trial."

ICH E6(R2) 4.1.5: "The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions."

ICH E6(R2) 4.2.5: "The investigator may delegate... but retains responsibility for the conduct of the trial at the site."

Therefore, the investigator/institution (B) must implement procedures and oversight to maintain integrity of trial duties.

Reference:

ICH E6(R2) Good Clinical Practice, §4.1.1; §4.1.5; §4.2.5 (Investigator responsibilities; delegation and oversight).

Reveal Solution Next Question

QUESTION: 6

In accordance with the CFR, a sponsor must submit a protocol amendment to the FDA for which of the following?

The addition of a new test that is intended to improve monitoring the subject for an adverse effect
A significant change in an investigator's financial interest in the investigational product
The addition of a sub-investigator with the scientific training and expertise to conduct the investigation
A change in the manufacturing site for the investigational product

Answer(s): D

Explanation:

The U.S. Code of Federal Regulations (CFR) specifies when sponsors must notify FDA of changes to investigational drug studies under 21 CFR 312.30. A protocol amendment is required if there is:

A change to the protocol (e.g., objectives, design, subject population, dosing, or procedures).

The addition of a new investigator.

A change in the chemistry, manufacturing, or controls (CMC) that could significantly affect product quality or safety.

Among the listed options, a change in the manufacturing site (D) directly falls under significant manufacturing changes, requiring FDA submission. Changes in investigator financial interests (B) are covered under 21 CFR 54 and reported separately, not as protocol amendments. Addition of a sub- investigator (C) does not require a formal amendment, only site-level documentation and delegation log update. Addition of a monitoring test (A) may affect the protocol, but not necessarily mandate an amendment unless it changes objectives or subject safety endpoints.

Therefore, the correct answer is D. This ensures FDA oversight of product safety, efficacy, and compliance with CMC standards before investigational use.

Reference:

21 CFR 312.30 (Protocol amendments).

21 CFR 312.23(a)(7) (Chemistry, manufacturing, and controls information).

Reveal Solution Next Question

QUESTION: 7

In an IND study, the specified dosage of an investigational product is 2 mg twice a day for 10 days. The product is available in 1 mg tablets. The subject was given 45 tablets and was instructed to take 2 mg of the product twice a day for 10 days. How many tablets should the subject have after the 10

days?

Answer(s): C

Explanation:

This question tests drug accountability and dosing calculation, which is central to ICH E6(R2) 4.6 (Investigational product management). Subjects must receive the correct supply and any discrepancy must be reconciled.

The prescribed regimen is 2 mg twice daily = 4 mg per day. With 1 mg tablets, this equals 4 tablets daily. Over 10 days, the subject should consume 40 tablets (4 × 10 = 40). Since 45 tablets were dispensed, the subject should have 5 tablets remaining after 10 days.

Accurate accountability ensures trial integrity and subject safety. Investigators are responsible for maintaining investigational product (IP) records, including dispensing, usage, and returns. According to ICH:

4.6.3: "The investigator/institution should maintain records of the product's delivery to the trial site, the inventory, the use by each subject, and the return to the sponsor or alternative disposition."

4.6.5: "The investigator should ensure that investigational products are used only in accordance with the approved protocol."

Thus, the correct answer is C (5 tablets remain). This reflects proper dosing compliance and highlights the importance of meticulous IP tracking in clinical trials.

Reference:

ICH E6(R2), §4.6 (Investigational Product(s)).

Reveal Solution Next Question

QUESTION: 8

According to the CFR and the ICH GCP Guideline, which of the following must be submitted to the IRB after completion of the trial at the site?

The final report
The monitoring close-out visit report
The data safety monitoring summary
The final subject enrollment log

Answer(s): A

Explanation:

When a trial ends at a site, the investigator has an obligation to submit a final report to the IRB/IEC.
This is outlined in both ICH and CFR:

ICH E6(R2) 4.13: "Upon completion of the trial, the investigator should provide the IRB/IEC with a summary of the trial's outcome."

21 CFR 312.66: Requires investigators to "report to the IRB all changes in the research activity and all unanticipated problems involving risk, and to provide reports at the end of the study."

The final report provides closure and documentation that the study was conducted ethically and in compliance with regulatory standards. Other documents listed in the options (monitoring reports, DSMB summaries, subject logs) may be retained by the sponsor or site, but they are not mandated for IRB submission.

Thus, the correct answer is A (Final Report). This ensures the IRB/IEC has an accurate record of study completion, outcome, and compliance with ethical oversight.

Reference:

ICH E6(R2), §4.13 (Final reporting to IRB/IEC).

21 CFR 312.66 (IRB review and reporting).

Reveal Solution Next Question

SOCRA Certified Clinical Research Professional CCRP Dumps in PDF

Free SOCRA CCRP Real Questions (page: 1)

QUESTION: 1

Explanation:

Reference:

QUESTION: 2

Explanation:

Reference:

QUESTION: 3

Explanation:

Reference:

QUESTION: 4

Explanation:

Reference:

QUESTION: 5

Explanation:

Reference:

QUESTION: 6

Explanation:

Reference:

QUESTION: 7

Explanation:

Reference:

QUESTION: 8

Explanation:

Reference: